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Abstract Ischemic preconditioning (IPrec) improves post-is-
chemic dysfunctions of the myocardium along with activation
of protein kinase C isozymes including PKCN. Moreover, ex-
pression of cardio-protective determinants can reduce ischemic
damages. Because IPrec is limited in aged hearts, we assessed in
an experimental model the impact of aging on PKCN and se-
lected protective proteins in the preconditioned myocardium
from adult (955) and older (v70 years) humans. Adult myo-
cardium showed PKCN up-regulation after IPrec along with
improved post-ischemic contractility. Although there was no
functional bene¢t, PKCN increased in older myocardium as
well. Subsequent mRNA analyses demonstrated that IPrec sta-
bilizes the mRNA expression of protective proteins (Hsp70, Bcl-
2/-xL, IAPs) in both aging groups. Moreover, older hearts re-
vealed increase in post-ischemic Hsp90L. Our study indicates,
that IPrec conserves the expression of cardio-protective deter-
minants in aged hearts despite limited functional recovery.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The pre-treatment of the myocardium with brief intervals of
cardiac ischemia and reperfusion diminishes the myocardial
damage induced by prolonged ischemia. This phenomenon
is called ischemic preconditioning (IPrec) [1]. Mechanisms
underlying the protection by preconditioning include the acti-
vation of G-coupled surface receptors, protein kinase C
(PKC) translocation and opening of mitochondrial KATP
channels (review [2]). Moreover, the activation of several pro-
tective determinants after ischemic pre-treatment might con-
tribute to a reduced cell death by necrosis, such as inducible
heat shock proteins [3], or by apoptosis like some members of
the Bcl-2 family [4]. However, there is no strict discrimination
of apoptotic and necrotic cell loss, especially in ischemia.
While heat shock proteins are involved in apoptosis pathways
as well [5], Bcl-2 proteins can reduce necrosis by antagonizing
mitochondrial dysfunctions [6].
Recently, we demonstrated that IPrec has no bene¢cial ef-
fect on the post-ischemic contractile function of aged human
myocardium [7]. This limitation is a crucial determinant in the
surgical treatment of elderly with coronary artery disease and
other heart failures. Because the underlying mechanisms are
barely investigated, this study aimed to assess the impact of
aging on cardio-protective factors involved in ischemia and
preconditioning.
Using an in vitro model, the level of the inducible hsp70
isoforms Hsp70-1 and Hsp70-2 was analyzed in isolated myo-
cardium from adult and older heart surgery patients after
ischemia and reperfusion. Both gene variants encode for the
identical Hsp70 protein but are sequentially regulated [8].
Their divergent 3P-untranslated region allows speci¢c mRNA
analyses demonstrating that Hsp70-2 is induced by short-term
ischemia, whereas Hsp70-1 induction is related to long-term
ischemic conditions [9]. In addition to Hsp70, the expression
of Bcl-2 proteins (Bcl-2, Bcl-xL) and of members of the in-
hibitor of apoptosis (IAP) family (hIAP-1, XIAP) was of spe-
cial interest. hIAP-1 and XIAP e¡ectively block the activity of
apoptosis-related caspases and promote the nuclear factor
(NF)-UB-mediated cell survival via NF-UB stimulation, too
[10]. Proteolytic activation of caspases is the central element
of the apoptotic machinery that ¢nally results in the process-
ing of a large variety of cellular substrates thereby contribut-
ing to the characteristic morphological and biochemical
changes during apoptosis (review [11]). Two of those sub-
strates are PKCN and Hsp90L, which are directly involved
in cellular stress situations. While PKCN is one of the PKC
isoforms activated in cardiomyocytes after IPrec, the Hsp90L
protein impairs together with Hsp70 the execution phase of
apoptosis down-stream of caspase activation [12]. Therefore,
we investigated the impact of aging on PKCN, Hsp90L and
other protective proteins in the preconditioned myocardium.
2. Materials and methods
2.1. Experimental procedure
Right atrial appendages obtained from adult (9 55 years, n=15)
and older patients (v 70 years, n=15) undergoing coronary bypass
surgery were used in this study as previously described [7]. All patients
su¡ered from coronary artery disease. Four trabeculae from each
appendage were placed in an organ bath with continuously oxygen-
ated Tyrode’s solution. Specimens were electrically stimulated at 1 Hz
and the force of contraction was registered (Hugo Sachs Electronics,
Germany). Trabeculae were subjected to 30 min of experimental is-
chemia (hypoxic substrate-free Tyrode’s solution) in combination with
rapid pacing at 3 Hz, followed by 90 min of reoxygenation (normoxic
solution periodically exchanged, stimulation at 1 Hz). In each experi-
ment, two trabeculae were ischemically preconditioned for 5 min,
followed by 10 min of reoxygenation. The isometric force was ex-
pressed as the percentage force of pre-ischemic baseline values. Tra-
beculae of additional patients (55^70 years, n=10), which were super-
fused in the same time course without ischemia (non-ischemic) and
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with ischemia (ischemic), served as independent control group. The
use of human material was approved by the local ethics committee.
For characteristics of patients and functional data of trabeculae see
Table 1.
2.2. Reverse transcription-polymerase chain reaction (RT-PCR)
At the end of each reoxygenation, both ischemic controls as well as
both preconditioned trabeculae from the same patient were pooled.
Total RNA was extracted using the TRIzol0 reagent (Invitrogen, The
Netherlands) and cleaned up with RNeasy columns (Qiagen, Chats-
worth, CA, USA). RNA quality was controlled by agarose gel elec-
trophoresis and quantity was determined by UV/Vis spectrophotom-
etry. In a RT reaction, cDNA was synthesized from 200 ng of RNA
with 100 U Superscript II1 reverse transcriptase (Invitrogen). 2.5 Wl
cDNA reaction was used for PCR containing 1.5 mM MgCl2, 5 pmol
of each gene-speci¢c primer (Table 2), 10 WM of each dNTP, and 1 U
rTaqDNA polymerase (Promega, USA). PCR ampli¢cation was per-
formed in a thermocycler (Biometra, Germany). After gel electropho-
retic separation, intensity of PCR products was densitometrically eval-
uated using the AIDA 2.0 software (Raytest, Germany).
2.3. Western blot analysis
Total protein was extracted from the protein phase of the TRIzol0
preparation according to manufacturer’s instruction (Invitrogen), and
concentration was measured by the BCA protein assay (Sigma-Al-
drich, Germany). Samples containing 20 Wg of protein were separated
by SDS^PAGE and blotted onto nitrocellulose membrane. Non-trans-
ferred protein was visualized by staining of the analytic gel with Coo-
massie blue solution. Proteins bound to the blotting membrane were
blocked with non-fat dry milk in TBST bu¡er (200 mM Tris^HCl, pH
7.5; 300 mM NaCl; 0.1% Tween 20) and incubated with the respec-
tive anti-human antibody: goat polyclonal Hsp90L and rabbit poly-
clonal PKCN (both are from Santa Cruz Biotech, Santa Cruz, CA,
USA), p20 Caspase-3 (Cell Signaling, USA), Caspase-9 (BD Pharmin-
gen) and mouse monoclonal actin (Sigma, St. Louis, MO, USA).
Bound antibodies were detected by horseradish peroxidase-conjugated
secondary antibodies (Dianova, Germany). Chemiluminescence detec-
tion was performed with ECLplus solution and Hyper¢lm ECL (Amer-
sham Bioscience, UK). Visualized signals for antibody detection and
for total protein bands of the Coomassie blue-stained gel were densi-
tometrically quanti¢ed. All analytic gels contained loading samples
for the internal signal correction.
2.4. Data analysis
Data are meansPS.E.M. Paired sample sets were always analyzed
side by side. Densitometrically determined values are expressed
as optical density units (opt. density U). For comparison of pre-
conditioned myocardium with the ischemic control of the same pa-
tient, Student’s paired t-test was used (SigmaStat software, Jandel
Corp., USA). For evaluation of independent data, Student’s unpaired
t-test was applied. P9 0.05 indicates a signi¢cant di¡erence of mean
values.
3. Results
This study demonstrated that atrial trabeculae from adult
heart surgery patients show a higher baseline contractility
(Table 1) and a signi¢cantly better preservation of the post-
ischemic function by IPrec than trabeculae from the elderly
(Fig. 1, Table 3). The contractile force recovery was deter-
mined by 55P 5.5% after reoxygenation compared to
44P 6.0% in non-preconditioned ischemic controls (P=0.05).
In contrast, preconditioning had no protective e¡ect on tra-
beculae from patients older than 70 years (Table 3).
To assess the molecular basis of our observation, total
RNA and protein were extracted from atrial trabeculae after
reoxygenation and analyzed in age-dependent manner. As
summarized in Table 3, total mRNA expressions of Hsp70-1
and Hsp70-2 were signi¢cantly increased by preconditioning
in the myocardium from adult patients. Although older pa-
tients had no improved contractile function in response to
preconditioning, both Hsp70 mRNAs were increased to sim-
ilar extent. The same tendency was observed for Bcl-2 mRNA
in the adult patient group and for Bcl-xL mRNA in the older
patients. When studying IAP proteins, we found higher levels
of hIAP-1 and XIAP mRNA in the preconditioned myocar-
dium as well.
Table 1
Data of coronary artery patients included in this experimental study
Group Adult patients Older patients
Clinical characteristics of patients
Age (years) 49P 1 74P 1
Angina pectoris stage II II
Left ventricular EF (%) 59P 4 61P 3
Mean aortic pressure (mm Hg) 83P 3 83P 5
Drug therapy
L-blockers 11 10
ACE inhibitors 9 8
Nitrates 8 7
Baseline data of atrial trabeculae
ICo IPrec ICo IPrec
Force of contraction (Nm) 4.9 P 0.6# 5.2 P 0.5# 3.6P 0.4 3.9 P 0.3
Pulse amplitude (V) 10.4P 0.4 9.3 P 0.3 10.3P 0.3 9.6 P 0.3
Weight (mg) 5.9 P 0.7 6.1 P 0.5 5.1P 0.6 4.9 P 0.5
Data are meansPS.E.M. (n=15 each study group); #P6 0.05 vs. respective data of the older patient group (unpaired t-test). ACE, angioten-
sin-converting enzyme; EF, ejection fraction; ICo, ischemic control samples; IPrec, trabeculae pretreated with 5 min IPrec.
Fig. 1. Post-ischemic recovery of the contractile force of atrial tra-
beculae from individual adult patients (9 55 years) and older pa-
tients (v 70 years). Data are calculated 90 min after reoxygenation
as percentage of pre-ischemic baseline values.
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Detailed analyses of constitutively expressed (‘house-keep-
ing’) genes, which are frequently used for data correction of
inter-sample variations, revealed that the total expression of
L-actin mRNA but also of the ribosomal 18S rRNA is im-
proved in the preconditioned myocardium compared to non-
preconditioned controls (Fig. 2). Interestingly, the myocardial
level of 18S rRNA and of other target mRNAs directly corre-
lated with the post-ischemic contractile force. This was ob-
vious for the total mRNA expression of both IAP proteins
(hIAP-1, XIAP) and Bcl-2 proteins (Bcl-2, Bcl-xL) in the en-
tire study group (rs 0.39, n=30, P9 0.05 in all cases). For
Hsp70-1, but not for Hsp70-2, we also found positive corre-
lations using the di¡erential evaluation mode (i.e. contractile
force recovery of preconditioned trabeculae minus internal
non-preconditioned control ; r=0.38, P=0.05).
Based on the fact that data calculations in relation to
‘house-keeping’ genes may result in misleading interpretations
of the gene expression, all mRNA data are given per total
RNA amount used in each analysis. Instead, a separate pa-
tient group was created (n=10). Trabeculae of this group
were superfused in the same time course but without ischemia.
The direct comparison of mRNA levels in the preconditioned
ischemic myocardium with those in non-ischemic controls
clearly showed that the ischemic pre-treatment does not in-
duce but stabilizes the mRNA expression which was indeed
decreased in most non-preconditioned specimens (Table 3).
Age-dependent di¡erences have not been determined.
The strong impairment of ischemia on the mRNA expres-
sion machinery was not identi¢ed for the protein expression.
Neither the protein levels of L-actin nor of Hsp-90L and
PKCN were signi¢cantly changed in the ischemic myocardium
compared with non-ischemic controls (Figs. 2 and 3). Hsp90L
was stably expressed after ischemia with and without ischemic
preconditioning, too. On the other hand, specimens from the
older myocardium were characterized by a two-fold increase
in Hsp90L protein. In contrast, the post-ischemic expression
of PKCN was induced after preconditioning which can be
determined in both aging groups (Fig. 4). Simultaneous anal-
yses of the proteolysis of PKCN and Hsp90L by caspases re-
vealed cleavage products for PKCN but not for Hsp90L. The
PKCN fragment p43 was processed in trabeculae after ische-
mic intervention (Fig. 3). Preconditioning had no in£uence on
the formation of p43 per entire PKCN which was determined
with 19P 3.6% in the preconditioned trabeculae and 18P 3.8%
in ischemic controls (n=30). Although there were no age-de-
pendent di¡erences in the percentage cleavage of PKCN, older
patients tended to a higher total level of p43 PKCN in the
post-ischemic myocardium (Fig. 3).
Ischemia-reperfusion occurs along with mitochondrial dys-
functions and the release of cytochrome c into the cytosol that
triggers the caspase cascade via activation of caspase-9 [13].
Therefore, caspase-9 and its down-stream target caspase-3
were additionally investigated. These analyses revealed that
neither caspase-9 nor caspase-3 are processed into active p35
caspase-9 or active p20 caspase-3 on detectable level (data not
shown).
4. Discussion
The hallmark of IPrec is the preservation of myocardial
structure and cardiac function [14]. However, animal studies
showed that aging is a limiting determinant for the myocardial
Table 2
Primers for RT-PCR analysis
mRNA Accession number 5P^3P sequence primer
Sense Antisense
Bcl-2 M14745 GACTTCTTCCGCCGCTACCG GACAGCCAGGAGAAATGAAAC
Bcl-xL Z23115 GGTGGTTGACTTTCTCTCCTAC GAAAAGTATCCCAGCCGCC
L-actin XM037235 GAAGTGTGAGTGGACATCCG AGCATTTGCGGTGGACGAT
hIAP-1 AF070674 GTTCATCCGTCAAGTTCAAG GTTCTTTCTTCTGGTAGTCTCC
Hsp70-1 XM004188 CCGAGAAGGACGAGTTTGAG GGAAATGCAAAGTCTTGAAGC
Hsp70-2 XM004189 CCGAGAAGGACGAGTTTGAG TCGTACAGAAGGTGGCAGTG
XIAP U32974 GATGCTGTGAGTTCTGATAGG CTTAATGTCCTTGAAACTGAAC
18S rRNA M10098 GTTGGTGGAGCGATTTGTCTGG AGGGCAGGGACTTAATCAACGC
Table 3
Post-ischemic functional data of atrial trabeculae and expression of cardio-protective determinants
Non-ischemic controls Adult group Older group
ICo IPrec ICo IPrec
Developed force of contraction (% vs. baseline)
Force (%) 67.1P 7.8# 44P 6.0 55P 5.5* 44P 3.9 46P 5.1
Total mRNA level (opt. density U)
18S rRNA 181P 16.1# 123P 20.6 168P 11.3* 118P 18.1 159P 15.6*
L-actin 176P 5.9 147P 14.4 180P 10.0* 143P 12.4 168P 11.7*
Hsp70-1 425P 29.5# 251P 29.5 332P 27.1* 218P 30.1 279P 30.7*
Hsp70-2 191P 22.4 143P 30.4 182P 27.2* 99.2P 14.5 141P 16.9*
Bcl-2 208P 12.2 159P 19.8 204P 14.7* 142P 16.4 175P 16.0
Bcl-xL 176P 31.5# 105P 24.1 145P 19.5 92.3P 18.2 145P 16.3*
hIAP-1 116P 20.5# 72.1P 17.1 105P 10.9* 60.1P 12.5 96.3P 13.6*
XIAP 194P 68.4 158P 54.6 258P 52.7 154P 42.8 228P 47.5*
Mean dataPS.E.M. (n=10, non-ischemic control group; n=15, group of adult and older patients); *P6 0.05 vs. ischemic control (paired t
test); #P6 0.05 vs. ischemic control values of the entire study group (unpaired t-test). ICo, non-preconditioned ischemic control trabeculae;
IPrec, trabeculae subjected to 5 min ischemic preconditioning.
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protection achieved with IPrec [15]. For ethical reason the
impact of age in human myocardium is more indirectly drawn
from clinical reports (review [16]). Therefore, we established
an experimental model studying isolated myocardium of heart
surgery patients [7]. In this study we clearly demonstrated that
ischemic preconditioning has bene¢cial e¡ect on adult human
myocardium, whereas it fails to preserve the contractile func-
tion from a sustained ischemia in older patients.
Several cellular mechanisms are associated with IPrec in-
cluding the PKC-dependent activation of mitochondrial
KATP channels that ¢nally preserves the mitochondrial func-
tion (review [17]). PKC appears to be the ¢rst element of a
complex kinase cascade that is activated during ischemia in
the preconditioned heart. Cardiac myocytes contain at least
six di¡erent PKC isoforms [18] but preconditioning results in
the activation of only two, namely PKCO and PKCN [19].
Depending on the experimental model and species used, the
induction of PKCK and PKCR by simulated ischemia [20] or
pharmacological agents that lead to cardio-protection from
ischemia [21] is described as well. Although the inability of
most antagonists to discriminated among multiple PKC iso-
forms does limit speci¢c investigations of the PKC signalling,
PKCN might play a critical role in modulating the mitochon-
drial function because PKCN directly translocates to mito-
chondria after its activation [21]. In our study, we observed
an increased level of PKCN in the preconditioned myocardium
of adult and older patients to similar extent. Although the
PKCN up-regulation does not describe its activation by sub-
cellular translocation, this observation can not directly con-
¢rm data of Tani et al. suggesting a reduced PKCN activity as
a limiting factor in the preconditioning response of aged
hearts [22]. While the protective role of PKCO was clearly
shown [19], it is still controversial whether PKCN does con-
tribute to myocardial protection. PKCN activation was found
to play an essential role in the opioid-mediated cardio-protec-
tion against ischemia [23] but other studies using PKC-selec-
tive antagonists demonstrated that PKCN enhances the ische-
mia-induced damage of cardiomyocytes [24]. Moreover,
PKCN is required for apoptotic cell death and the caspase-
speci¢c cleavage of PKCN into p43 PKCN further ampli¢es
this process by generating an active kinase domain that trans-
locates to mitochondria and rapidly induces mitochondrial
dysfunction [25]. The tendency of aged myocardium to pro-
cess higher levels of post-ischemic p43 PKCN is a possible
explanation why older patients do less respond to cardio-pro-
tection after ischemic pre-treatment. However, we did not ¢nd
a relation of PKCN level and p43 generation with the less
e¡ective preconditioning response in older hearts suggesting
a more complex network of the entire PKC action in the
preconditioned myocardium. In this context, it has to keep
in mind that other PKC isozymes are also targets of the cas-
pase proteolysis including the cardio-protective PKCO [25].
Fig. 2. Post-ischemic mRNA and protein level for L-actin in preconditioned atrial trabeculae (IPrec) and ischemic controls (ICo) for all patients
of study (n=30). Data are shown in comparison with the 18S rRNA expression which positively correlates with the functional recovery.
#Correction of inter-sample variations per total protein staining.
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Although caspase-speci¢c cleavage products have been
identi¢ed for PKCN, it is unknown to what extent apoptotic
caspases are still active during the post-ischemic period be-
cause we did not identify the generation of active caspase-3
and -9 after 90 min of reoxygenation. This might base on the
fact that oxidized conditions can modify the caspase activity.
Caspases are redox-sensitive enzymes and prolonged oxidative
stress, as happening in post-ischemic reperfusion, can convert
active caspases to an inactive state [26]. Unfortunately, the
amount of trabeculae material was limited to analyze the en-
zymatic activity of caspases in addition. Moreover, the expres-
sion of heat shock proteins can mediate caspase inhibition.
Hsp90L and Hsp70 block the activity of caspase-9 via seques-
tration of its cofactor Apaf-1 [12]. An age-dependent impact
on this process is not yet described.
In contrast to PKCN, for Hsp90L we neither identi¢ed the
cleavage at caspase-speci¢c site in the ischemic myocardium
nor an altered expression after IPrec. Although Hsp90 up-
regulation is shown in preconditioned cardiomyocytes [27],
there are also opposite reports [28] con¢rming our ¢ndings.
Hsp90L was elevated in the ischemic myocardium of older
patients suggesting a physiological role of Hsp90L in the pro-
tection of aged hearts. In this context, an increase in Hsp90L
might counteract the reduced tolerance of the aged myocar-
dium to ischemia frequently reported [29], but the association
with ischemia-independent aging processes is possible as well.
In contrast to Hsp90L, the Hsp70 expression was not signi¢-
cantly changed in older myocardium after ischemia and pre-
conditioning. However, IPrec stabilized the total mRNA level
of Hsp70-1/-2 but also of Bcl-2, Bcl-xL, hIAP-1 and XIAP
against prolonged ischemia in adult but also in aged myocar-
dium. This seems to base on a general protection of the tran-
scription machinery and/or mRNA stability, that frequently
correlated with the recovery of the post-ischemic cardiac func-
tion. As indicated by L-actin mRNA, the myocardial level was
reduced after ischemia-reoxygenation compared to non-ische-
mic controls but to less extent in the preconditioned myocar-
dium. Because the protein level of L-actin was not a¡ected by
ischemia, this seems to be a mRNA-related mechanism.
The most common approach to correct inter-sample varia-
tions of transcription analyses is the normalization per con-
stitutively expressed control genes like L-actin. Because the
Fig. 3. Western blot analysis of Hsp90L, PKCN and its cleavage
product p43 PKCN in the post-ischemic myocardium (I) in compari-
son with the internal non-ischemic control (C) from individual pa-
tients (A to D) of intermediate age (55^70 years). Data of the age-
dependent protein level of the active p43 PKCN subunit in non-pre-
conditioned ischemic controls are shown below. #Inter-sample cor-
rection per L-actin and total protein staining.
Fig. 4. Post-ischemic level of PKCN and Hsp90L protein in preconditioned atrial trabeculae (IPrec) and ischemic controls (ICo) from adult and
older patients (n=15 each study group). #Correction of inter-sample variations per L-actin and total protein staining.
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steady-state levels of such ‘house-keeping’ genes cannot al-
ways be assumed under hypoxic and other stress conditions
[30], we included the quanti¢cation of ribosomal RNA (18S
rRNA). However, even ribosomal RNA can be impaired as a
consequence of sub-lethal stress insults [31] as demonstrated
in our study as well. For this obvious impact by ischemia, we
represented our data per analyzed amount of total RNA
as usually done in standard-calibrated competitive PCR or
in real-time PCR analysis. Nevertheless, the stress-altered
mRNA expression of ‘house-keeping’ genes is critical and
can result in faulty data calculations, especially for slightly
changed expressions. This might have lead to controversial
reports in the past. Based on the fact that the post-ischemic
mRNA level of genes including several cardio-protective de-
terminants was improved after preconditioning, our transcrip-
tion analyses demonstrate a protecting e¡ect on molecular
level in addition to the functional recovery of the myocardi-
um. Age-dependent di¡erences in the expression of protective
determinants, including Hsp70 and Bcl-2 proteins, have not
been determined. These observations support data of Loubani
et al. revealing that age does not in£uence the bene¢t of pre-
conditioning on structural basis of human trabeculae [32],
furthermore suggesting di¡erences between the functional
and morphological preservation after preconditioning.
Taken together, our study indicates that the post-ischemic
expression of determinants involved in IPrec is still preserved
in aged hearts despite less functional bene¢t in response to
preconditioning. This has been shown for PKCN induction in
the preconditioned myocardium but also for the stable expres-
sion of selected cardio-protective determinants suggesting a
more complex network of factors responsible for the age-de-
pendent functional decline in the preconditioning response.
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